Cargando…
Favipiravir exposure and pregnancy outcome of COVID-19 patients
OBJECTIVE: COVID-19 is a rapidly spreading disease and many people have been infected in a short time. Favipiravir is under investigation for the treatment of COVID-19 and given to patients in many countries following emergency use approval. Based on data from animal studies, favipiravir use is cont...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647391/ https://www.ncbi.nlm.nih.gov/pubmed/34902747 http://dx.doi.org/10.1016/j.ejogrb.2021.12.001 |
_version_ | 1784610597519753216 |
---|---|
author | Tırmıkçıoğlu, Zeynep |
author_facet | Tırmıkçıoğlu, Zeynep |
author_sort | Tırmıkçıoğlu, Zeynep |
collection | PubMed |
description | OBJECTIVE: COVID-19 is a rapidly spreading disease and many people have been infected in a short time. Favipiravir is under investigation for the treatment of COVID-19 and given to patients in many countries following emergency use approval. Based on data from animal studies, favipiravir use is contraindicated during pregnancy. Currently, there is no human data except for a single case report on use of favipiravir in pregnancy. STUDY DESIGN: This article includes the outcomes of 29 pregnancies reported to the Clinical Pharmacology and Toxicology Unit regarding favipiravir use in pregnancy. For drug risk assessment, maternal characteristics were obtained at first contact. After the expected day of delivery, follow-up is conducted by phone call and all relevant data regarding pregnancy and newborn outcome were documented. RESULTS: Of the 29 pregnancies exposed to favipiravir, 5 were electively terminated and 24 resulted in live birth. There were no miscarriages or no stillbirths. There were 25 live births including one pair of twins. Three children were born premature, and one infant had patent foramen ovale. Birth weights, lengths and head circumferences of all infants were within normal range. CONCLUSION: The results of the study indicate that favipiravir is unlikely to be a major human teratogen, but experience is still limited for a well-grounded risk assessment. Although these findings may be useful for the physicians and patients, larger studies are needed due to small number of cases. |
format | Online Article Text |
id | pubmed-8647391 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86473912021-12-06 Favipiravir exposure and pregnancy outcome of COVID-19 patients Tırmıkçıoğlu, Zeynep Eur J Obstet Gynecol Reprod Biol Article OBJECTIVE: COVID-19 is a rapidly spreading disease and many people have been infected in a short time. Favipiravir is under investigation for the treatment of COVID-19 and given to patients in many countries following emergency use approval. Based on data from animal studies, favipiravir use is contraindicated during pregnancy. Currently, there is no human data except for a single case report on use of favipiravir in pregnancy. STUDY DESIGN: This article includes the outcomes of 29 pregnancies reported to the Clinical Pharmacology and Toxicology Unit regarding favipiravir use in pregnancy. For drug risk assessment, maternal characteristics were obtained at first contact. After the expected day of delivery, follow-up is conducted by phone call and all relevant data regarding pregnancy and newborn outcome were documented. RESULTS: Of the 29 pregnancies exposed to favipiravir, 5 were electively terminated and 24 resulted in live birth. There were no miscarriages or no stillbirths. There were 25 live births including one pair of twins. Three children were born premature, and one infant had patent foramen ovale. Birth weights, lengths and head circumferences of all infants were within normal range. CONCLUSION: The results of the study indicate that favipiravir is unlikely to be a major human teratogen, but experience is still limited for a well-grounded risk assessment. Although these findings may be useful for the physicians and patients, larger studies are needed due to small number of cases. Published by Elsevier B.V. 2022-01 2021-12-06 /pmc/articles/PMC8647391/ /pubmed/34902747 http://dx.doi.org/10.1016/j.ejogrb.2021.12.001 Text en © 2021 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Tırmıkçıoğlu, Zeynep Favipiravir exposure and pregnancy outcome of COVID-19 patients |
title | Favipiravir exposure and pregnancy outcome of COVID-19 patients |
title_full | Favipiravir exposure and pregnancy outcome of COVID-19 patients |
title_fullStr | Favipiravir exposure and pregnancy outcome of COVID-19 patients |
title_full_unstemmed | Favipiravir exposure and pregnancy outcome of COVID-19 patients |
title_short | Favipiravir exposure and pregnancy outcome of COVID-19 patients |
title_sort | favipiravir exposure and pregnancy outcome of covid-19 patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647391/ https://www.ncbi.nlm.nih.gov/pubmed/34902747 http://dx.doi.org/10.1016/j.ejogrb.2021.12.001 |
work_keys_str_mv | AT tırmıkcıogluzeynep favipiravirexposureandpregnancyoutcomeofcovid19patients |